US FDA to take up Moderna, J&J COVID-19 booster questions this week

  • 📰 CNN Philippines
  • ⏱ Reading Time:
  • 70 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 31%
  • Publisher: 63%

Philippines Headlines News

Philippines Latest News,Philippines Headlines

Vaccine advisers to the US Food and Drug Administration meet Thursday and Friday of this week to tackle the next round of questions about booster vaccines for COVID-19 -- and they might be seeing the first trickle of data on mix-and-match boosters.

It's been one of the biggest ongoing questions about vaccines since three different products hit the US -- is it safe, and even desirable, to mix different vaccine types?

Researchers have been trying a variety of combinations."We first started off looking at people who have previously received Johnson & Johnson, Moderna and Pfizer and boosting those with an additional dose of Moderna vaccine," she said. The researchers have also tried boosting volunteers with Pfizer's and Johnson & Johnson's vaccine.

One head-to-head study led by the US Centers for Disease Control and Prevention found Moderna's vaccine was slightly more effective than Pfizer's in real-life use in keeping people out of the hospital.FDA staff were circumspect in documents posted ahead of Thursday's meeting."Some real world effectiveness studies have suggested declining efficacy of Moderna COVID-19 Vaccine over time against symptomatic infection or against the Delta variant, while others have not.

"Based on the recent data, it can be assumed that the administration of the booster dose will result in increased protection against symptomatic infection, increased strength and breadth of immune responses against current variants, and increase of the magnitude of protection against severe disease across populations," the company says in its application.

The committee will reconvene at 3:30 p.m. Friday to discuss the question of mix and match boosters -- although a vote is not scheduled on that question.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 13. in PH

Philippines Latest News, Philippines Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

DOH: Over 12,600 COVID-19 vaccine doses wastedThe wastage of 12,686 COVID-19 vaccine doses since March cost the country more than ₱6.9 million, according to one senator.
Source: CNN Philippines - 🏆 13. / 63 Read more »

Russia, EU to discuss terms for recognizing COVID-19 vaccine certificatesRussia and the EU will discuss terms for the mutual recognition of COVID-19 vaccine certificates for their respective shots at talks, the Interfax news agency cited Russia’s health ministry. | Reuters
Source: inquirerdotnet - 🏆 3. / 86 Read more »

DOH says 12,686 COVID-19 vaccine doses wastedMANILA, Philippines — Over 12,500 of the total 87 million COVID-19 vaccine doses so far received by the country have been wasted, an official of the Department of Health (DOH) revealed
Source: inquirerdotnet - 🏆 3. / 86 Read more »

Duterte accounts for COVID-19 vaccine shortage in PHPresident Rodrigo Duterte takes responsibility for PH COVID-19 vaccine shortage early this year. Killer and thief too. He could grab the Pfizer deal earlier but instead, he chooses to think it over after which the deadline expired and Singapore was given a priority instead. Sino pa bang mat responsibility nun?!
Source: CNN Philippines - 🏆 13. / 63 Read more »

Merck seeks US FDA emergency use authorization for antiviral COVID-19 treatment molnupiravirMerck says it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral COVID-19 treatment, molnupiravir.
Source: CNN Philippines - 🏆 13. / 63 Read more »

Merck seeks first US authorization for COVID-19 tabletMerck & Co Inc said on Monday it has applied for U.S. emergency use authorization for its tablet to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral
Source: cebudailynews - 🏆 8. / 71 Read more »